Ultragenyx: The first FDA approval in the gene therapy segment - Experts raise the price target to $103!

The US health authority FDA has granted accelerated approval for the gene therapy Genglycos by Ultragenyx Pharmaceutical Inc. (RARE). Analyst Kristen Kluska from Cantor Fitzgerald subsequently raised the price target for the stock to $103. This corresponds to a potential upside of around 260% at present! For the company, this marks the first approved gene therapy and strengthens its business model focused on rare diseases. Specialization in rare genetic diseases as a foundation Ultragenyx Pharmaceutical (RARE) operates in the biotechnology...